SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria: 1. Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy 2. Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen. 3. Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable. 4. Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500. Exclusion Criteria: 1. Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable) 2. Active treatment for cancer 3. Active treatment for hepatitis C requiring interferon based therapy 4. Immunosuppressive therapy taken within the last 4 months
About the study
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.
Sponsor: University of California, San Francisco · Participants: 2,500 · Started: 2000-03
Contact the study team
- Rebecca Hoh, M.S., R.D. · Phone: 415-476-4082
- Montha Pao · Phone: 415-476-4082
Official record on ClinicalTrials.gov — NCT00187512
Locations in the U.S.
| California | San Francisco General Hospital, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.